Assyro AI
Orange Book product · Brand (NDA)

Advair Hfa

Fluticasone Propionate; Salmeterol Xinafoate

Brand (NDA)NDA 021254RLD Glaxo Grp Ltd
Approved
Jun 08, 2006
Application
Brand (NDA)
TE code
Not listed
Listed patents
0
Advair Hfa (Fluticasone Propionate; Salmeterol Xinafoate) is Glaxo Grp Ltd's brand-name drug, approved by the FDA under NDA 021254 in 2006. It is a reference-listed drug (RLD) — the approved product that generic ANDA applicants must show their version is equivalent to. 4 approved generics share this drug's active ingredient.

Sourced from the FDA Orange Book

Approval, patents, exclusivity

Key dates

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jun 08, 2006

    20 yr 5 mo ago

  2. Today

FDA product record

Pharmaceutical detail

Pharmaceutical detail

Active ingredient

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

Strength

0.115MG/INH;EQ 0.021MG BASE/INH

Dosage form

AEROSOL, METERED

Route

INHALATION

TE code

Not listed

Application

NDA 021254

Product number

002

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Same application

Other strengths in NDA 021254

Brand + generics

Active-ingredient family

Orange Book patent file

Listed patents

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Advair Hfa — frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this product, from the FDA Orange Book.

Built directly from the FDA Orange Book data file. This product page links back to the Fluticasone Propionate; Salmeterol Xinafoate active-ingredient family, which is the canonical reference for generics, patents, and exclusivity across all strengths.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.